clinical trial · NCT05064085
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute·phase1·completed·n = 13
Hormone Receptor-positive Breast CancerCemiplimabCapecitabine
brief summary
This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor-positive (HR+) metastatic breast cancer.
started
Oct 12, 2021
primary completion
Sep 9, 2024
completion
Mar 13, 2025
last updated
Jul 2, 2026
official title
A Phase I Trial of Capecitabine in Combination With Cemiplimab in Patients With Hormone Receptor Positive Metastatic Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol